CTMX
Companies
NASDAQ
CytomX Therapeutics Inc.
Health Care
$2.21
+$1.18 (+114.56%)
Price Chart
Overview
About CTMX
CytomX Therapeutics Inc is an oncology-focused biopharmaceutical company that is operating in the United States. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.
Market Cap
$127.8M
Volume
2.5M
Avg. Volume
6.3M
P/E Ratio
-0.72948277
Dividend Yield
0.00%
Employees
139.0
Company Information
Risk & Correlation Analysis
Market Correlation
2.03
High Correlation
Volatility
High (0.96)
Relative to market
Macro Factor Sensitivities
Interest Rates
Medium Sensitivity
Inflation
High Sensitivity
GDP Growth
Low Sensitivity
Liquidity
Low Sensitivity
Commodity Prices
Medium Sensitivity
Credit Quality
High Sensitivity
Portfolio Impact
Forecasts & Predictions
1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential
Technical Analysis
Based on technical indicators and chart patterns, CTMX shows...
AI Sentiment Analysis
Market sentiment analysis indicates...
Key Statistics
Market Cap$127.8M
Volume2.5M
P/E Ratio-0.73
Dividend Yield0.00%
Important Dates
Next Dividend
Next Earnings
March 7, 2025Related Securities
Pricing info last updated June 19, 2025 (after market close)Other info last updated April 2, 2025